Fluicell

Fluicell Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Fluicell (FLUI.ST) as of Nov 20, 2026 is 59.35 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 101.02 % — a change of -41.25% (lower).

Cash Conversion

59.35 %

YoY

-41.25%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Fluicell is 2025 59.35 % . Cash Conversion Rate (OCF/Net Income) of Fluicell was 2024 101.02 % . It decreases by -41.25% lower compared to the previous year.

The Fluicell Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
84.78 SEK
Jan 1, 2019
91.60 SEK
Jan 1, 2020
96.78 SEK
Jan 1, 2021
85.82 SEK
Jan 1, 2022
97.93 SEK
Jan 1, 2023
102.53 SEK
Jan 1, 2024
101.02 SEK
Jan 1, 2025
59.35 SEK
The Fluicell Cash Conversion history
YEARCash ConversionYoY
59.35 %-41.25%
101.02 %-1.48%
102.53 %+4.70%
97.93 %+14.12%
85.82 %-11.32%
96.78 %+5.66%
91.60 %+8.05%
84.78 %-19.13%
104.83 %-5.60%
111.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

Cash Conversion Rate (OCF/Net Income) of Fluicell is 59.35 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Fluicell changed from 101.02 % to 59.35 %, representing a -41.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Fluicell since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Fluicell with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Fluicell

All Key Metrics — Fluicell